GSTT1, GSTM1, and GSTP1 polymorphisms as a prognostic factor in women with breast cancer

Genetics and Molecular Research

Volumn 13, Issue 2, 2014, Pages 2521-2530

  Oliveira, A L ^a   Oliveira Rodrigues, F F ^a   dos Santos, R E ^a   Rozenowicz, R L ^a   Barbosa de Melo, M ^b  

^a IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Breast cancer; Drug therapy; Genetic; Glutathione transferase; Polymorphism

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; ANTINEOPLASTIC AGENT; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GSTP1 PROTEIN, HUMAN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETIC POLYMORPHISM; GSTM1 GENE; GSTP1 GENE; GSTT1 GENE; HUMAN; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROSPECTIVE STUDY; AGED; BREAST NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; LYMPH NODES; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84897512317     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.January.22.9     Document Type: Article

References (38)

1. Adler V, Yin Z, Fuchs SY, Benezra M, et al. (1999). Regulation of JNK signaling by GSTp. EMBO J. 18: 1321-1334.
2. Ambrosone CB, Sweeney C, Coles BF, Thompson PA, et al. (2001). Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 61: 7130-7135.
3. Beeghly A, Katsaros D, Chen H, Fracchioli S, et al. (2006). Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol. Oncol. 100: 330-337.
4. Burg D and Mulder GJ (2002). Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug. Metab. Rev. 34: 821-863.
5. Cavalli SA, Otta MI, Hirata RDC and Nguyen NY (1996). Apolipoprotein E genotyping in Brazilian normocholesterolemic individuals. Clin. Chem. 42: (Suppl): S298.
6. Cho SG, Lee YH, Park HS, Ryoo K, et al. (2001). Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. J. Biol. Chem. 276: 12749-12755.
7. Dang DT, Chen F, Kohli M, Rago C, et al. (2005). Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res. 65: 9485-9494.
8. DeMichele A, Aplenc R, Botbyl J, Colligan T, et al. (2005). Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J. Clin. Oncol. 23: 5552-5559.
9. Fisher B, Ravdin RG, Ausman RK, Slack NH, et al. (1968). Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann. Surg. 168: 337-356.
10. Fisher B, Bryant J, Wolmark N, Mamounas E, et al. (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16: 2672-2685.
11. Hayes JD and Pulford DJ (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30: 445-600.
12. Hohaus S, Di Ruscio A, Di Febo A, Massini G, et al. (2005). Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin. Cancer Res. 11: 2175-2179.
13. Holley SL, Rajagopal R, Hoban PR, Deakin M, et al. (2006). Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. Int. J. Oncol. 28: 231-236.
14. Huang E, West M and Nevins JR (2003). Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent. Prog. Horm. Res. 58: 55-73.
15. Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300.
16. Jones BA, Christensen AR, Wise JP, Sr. and Yu H (2009). Glutathione S-transferase polymorphisms and survival in African-American and white colorectal cancer patients. Cancer Epidemiol. 33: 249-256.
17. Khedhaier A, Remadi S, Corbex M, Ahmed SB, et al. (2003). Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br. J. Cancer 89: 1502-1507.
18. Khrunin AV, Moisseev A, Gorbunova V and Limborska S (2010). Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10: 54-61.
19. Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, et al. (2009). GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 18: 2176-2181.
20. Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, et al. (2008). GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br. J. Cancer 99: 1316-1321.
21. L'Ecuyer T, Allebban Z, Thomas R and Vander HR (2004). Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am. J. Physiol. Heart. Circ. Physiol. 286: H2057-H2064.
22. Lahiri DK and Nurnberger JI, Jr. (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 19: 5444.
23. Leonessa F and Clarke R (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer 10: 43-73.
24. McIlwain CC, Townsend DM and Tew KD (2006). Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25: 1639-1648.
25. O'Brien ML and Tew KD (1996). Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer 32A: 967-978.
26. Oliveira AL, Rodrigues FF, Santos RE, Aoki T, et al. (2010). GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet. Mol. Res. 9: 1045-1053.
27. Rastogi P, Anderson SJ, Bear HD, Geyer CE, et al. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 26: 778-785.
28. Riddick DS, Lee C, Ramji S, Chinje EC, et al. (2005). Cancer chemotherapy and drug metabolism. Drug Metab. Dispos. 33: 1083-1096.
29. Rodrigues FF, Santos RE, Melo MB, Silva MA, et al. (2008). Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet. Mol. Res. 7: 177-183.
30. Salazar LA, Hirata MH, Cavalli SA, Machado MO, et al. (1998). Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin. Chem. 44: 1748-1750.
31. Shapiro DM and Fugmann RA (1957). A role for chemotherapy as an adjunct to surgery. Cancer Res. 17: 1098-1101.
32. Sweeney C, McClure GY, Fares MY, Stone A, et al. (2000). Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 60: 5621-5624.
33. Terek MC, Zekioglu O, Sendag F, Akercan F, et al. (2003). MDR1 gene expression in endometrial carcinoma. Int. J. Gynecol. Cancer 13: 673-677.
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92:205-216.
35. Townsend D and Tew K (2003a). Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3: 157-172.
36. Townsend DM and Tew KD (2003b). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22: 7369-7375.
37. Wilson MH, Grant PJ, Hardie LJ and Wild CP (2000). Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J. 14: 791-796.
38. Wolmark N, Wang J, Mamounas E, Bryant J, et al. (2001). Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 96-102.